Abstract
Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have